Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
H R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
H M Earl, L Hiller, J A Dunn, et al.
Journal of Clinical Microbiology
|
October 7, 2005
Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy
S Campana, G Taccetti, N Ravenni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2014
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients
H R Ali, E Provenzano, S-J Dawson, et al.
British Journal of Cancer
|
June 22, 2013
Tumour morphology predicts PALB2 germline mutation status
Z L Teo, E Provenzano, G S Dite, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
British Journal of Cancer
|
October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
H M Earl, L Hiller, J A Dunn, et al.
British Journal of Cancer
|
August 2, 2012
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
G C Wishart, C D Bajdik, E Dicks, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
H R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
H M Earl, L Hiller, J A Dunn, et al.
Journal of Clinical Microbiology
|
October 7, 2005
Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy
S Campana, G Taccetti, N Ravenni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2014
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients
H R Ali, E Provenzano, S-J Dawson, et al.
British Journal of Cancer
|
June 22, 2013
Tumour morphology predicts PALB2 germline mutation status
Z L Teo, E Provenzano, G S Dite, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
British Journal of Cancer
|
October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
H M Earl, L Hiller, J A Dunn, et al.
British Journal of Cancer
|
August 2, 2012
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
G C Wishart, C D Bajdik, E Dicks, et al.
Page
of 4